CervoMed Inc.
NCM: CRVOLive Quote
About CervoMed Inc.
Healthcare
Biotechnology
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodΒbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
π Fundamental Analysis
CervoMed Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -99.6% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -93.9%, which indicates that capital utilization is currently under pressure.
At a current price of $3.83, CRVO currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $3.51 - $13.13).
π₯ Financial Health
π΄
Profit Margin
Weak
π΄
Revenue Growth
Weak
π΄
Return on Equity
Weak
β
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$26.76M
Trailing P/E
--
Forward P/E
-2.26
Beta (5Y)
-5.04
52W High
$13.13
52W Low
$3.51
Avg Volume
86K
Day High
Day Low
π‘ Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App